Q-omics provides the consensus-scored LLPHP2 profile across patient tissues and cancer cell-line models. LLPHP2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LLPHP2 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, LLPHP2 RNA expression shows 12,299 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, LUSC, and THYM as cancer lineages where LLPHP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LLPHP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LLPHP2 survival associations across molecular data types. LLPHP2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LLPHP2 RNA expression–survival associations across cancer types. High LLPHP2 expression shows unfavorable associations in STAD, KIRP, KIRC and DLBC, but favorable associations in GBM and OV. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for LLPHP2 RNA expression.
This table summarizes LLPHP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LLPHP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LLPHP2 shows lower tumor expression in PAAD and THCA and higher tumor expression in LUSC, HNSC, BRCA and STAD. The LUSC box plot shows higher LLPHP2 RNA expression in tumor versus normal tissue (log2 FC = +0.127, t-test p = .005).
This table shows molecular features associated with LLPHP2 in patient tissues and cancer cell lines. In patient samples, LLPHP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
